Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults

P. Crovari, G. C. Icardi, P. Calcagno, S. Morganti, G. Cagetti, R. Bandettini, P. Bonanni

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

A clinical trial was conducted on 44 healthy young volunteers in order to assess the immunogenicity and safety of an inactivated hepatitis A vaccine. The preparation was injected intramuscularly in the deltoid region at month 0, 1, 6 and the serological follow-up was carried out at month 1, 2, 6, 7, 12. Each sample was tested for total anti-HAV with a new experimental kit manufactured by Boehringer Mannheim (B.M.) (Germany). Results were expressed as mIU/ml. Side effects after vaccine administration were relatively unfrequent and resulted to be mild, the most frequent being local pain at the site of injection. Seroconversion rates were 97.6% at month 1 and 100% at month 2. At all the following times (month 6, 7, 12) the presence of antibodies was maintained in all subjects. Anti-HAV Geometric Mean Titres resulted to be 379, 402, 486, 3917 and 1489 mIU/ml at month 1, 2, 6, 7 and 12 respectively. Two different kinetics of antibody response were noted at month 1 and 2. Most vaccinees increased their antibody titre after the second dose; some of them, however, showed a decrease of antibody titre after the second dose when compared to that achieved after the first one. Preliminary tests seem to explain such a behaviour with a decrease of IgM antibodies not yet compensated by an increase of IgG. The results of our study show how the inactivated hepatitis A vaccine is safe and highly immunogenic. Its use can be useful in subjects at risk of infections transmitted by the fecal-oral route, such as travellers from developed to developing countries.

Original languageEnglish
Title of host publicationJournal of Preventive Medicine and Hygiene
Pages111-115
Number of pages5
Volume33
Edition3-4
Publication statusPublished - 1993

Fingerprint

Hepatitis A Vaccines
Inactivated Vaccines
Young Adult
Hepatitis A Antibodies
Safety
Antibodies
Developing Countries
Antibody Formation
Germany
Immunoglobulin M
Healthy Volunteers
Vaccines
Immunoglobulin G
Clinical Trials
Pain
Injections
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Crovari, P., Icardi, G. C., Calcagno, P., Morganti, S., Cagetti, G., Bandettini, R., & Bonanni, P. (1993). Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. In Journal of Preventive Medicine and Hygiene (3-4 ed., Vol. 33, pp. 111-115)

Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. / Crovari, P.; Icardi, G. C.; Calcagno, P.; Morganti, S.; Cagetti, G.; Bandettini, R.; Bonanni, P.

Journal of Preventive Medicine and Hygiene. Vol. 33 3-4. ed. 1993. p. 111-115.

Research output: Chapter in Book/Report/Conference proceedingChapter

Crovari, P, Icardi, GC, Calcagno, P, Morganti, S, Cagetti, G, Bandettini, R & Bonanni, P 1993, Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. in Journal of Preventive Medicine and Hygiene. 3-4 edn, vol. 33, pp. 111-115.
Crovari P, Icardi GC, Calcagno P, Morganti S, Cagetti G, Bandettini R et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. In Journal of Preventive Medicine and Hygiene. 3-4 ed. Vol. 33. 1993. p. 111-115
Crovari, P. ; Icardi, G. C. ; Calcagno, P. ; Morganti, S. ; Cagetti, G. ; Bandettini, R. ; Bonanni, P. / Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. Journal of Preventive Medicine and Hygiene. Vol. 33 3-4. ed. 1993. pp. 111-115
@inbook{62bd8bf68a99410887f956569fc2ced0,
title = "Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults",
abstract = "A clinical trial was conducted on 44 healthy young volunteers in order to assess the immunogenicity and safety of an inactivated hepatitis A vaccine. The preparation was injected intramuscularly in the deltoid region at month 0, 1, 6 and the serological follow-up was carried out at month 1, 2, 6, 7, 12. Each sample was tested for total anti-HAV with a new experimental kit manufactured by Boehringer Mannheim (B.M.) (Germany). Results were expressed as mIU/ml. Side effects after vaccine administration were relatively unfrequent and resulted to be mild, the most frequent being local pain at the site of injection. Seroconversion rates were 97.6{\%} at month 1 and 100{\%} at month 2. At all the following times (month 6, 7, 12) the presence of antibodies was maintained in all subjects. Anti-HAV Geometric Mean Titres resulted to be 379, 402, 486, 3917 and 1489 mIU/ml at month 1, 2, 6, 7 and 12 respectively. Two different kinetics of antibody response were noted at month 1 and 2. Most vaccinees increased their antibody titre after the second dose; some of them, however, showed a decrease of antibody titre after the second dose when compared to that achieved after the first one. Preliminary tests seem to explain such a behaviour with a decrease of IgM antibodies not yet compensated by an increase of IgG. The results of our study show how the inactivated hepatitis A vaccine is safe and highly immunogenic. Its use can be useful in subjects at risk of infections transmitted by the fecal-oral route, such as travellers from developed to developing countries.",
author = "P. Crovari and Icardi, {G. C.} and P. Calcagno and S. Morganti and G. Cagetti and R. Bandettini and P. Bonanni",
year = "1993",
language = "English",
volume = "33",
pages = "111--115",
booktitle = "Journal of Preventive Medicine and Hygiene",
edition = "3-4",

}

TY - CHAP

T1 - Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults

AU - Crovari, P.

AU - Icardi, G. C.

AU - Calcagno, P.

AU - Morganti, S.

AU - Cagetti, G.

AU - Bandettini, R.

AU - Bonanni, P.

PY - 1993

Y1 - 1993

N2 - A clinical trial was conducted on 44 healthy young volunteers in order to assess the immunogenicity and safety of an inactivated hepatitis A vaccine. The preparation was injected intramuscularly in the deltoid region at month 0, 1, 6 and the serological follow-up was carried out at month 1, 2, 6, 7, 12. Each sample was tested for total anti-HAV with a new experimental kit manufactured by Boehringer Mannheim (B.M.) (Germany). Results were expressed as mIU/ml. Side effects after vaccine administration were relatively unfrequent and resulted to be mild, the most frequent being local pain at the site of injection. Seroconversion rates were 97.6% at month 1 and 100% at month 2. At all the following times (month 6, 7, 12) the presence of antibodies was maintained in all subjects. Anti-HAV Geometric Mean Titres resulted to be 379, 402, 486, 3917 and 1489 mIU/ml at month 1, 2, 6, 7 and 12 respectively. Two different kinetics of antibody response were noted at month 1 and 2. Most vaccinees increased their antibody titre after the second dose; some of them, however, showed a decrease of antibody titre after the second dose when compared to that achieved after the first one. Preliminary tests seem to explain such a behaviour with a decrease of IgM antibodies not yet compensated by an increase of IgG. The results of our study show how the inactivated hepatitis A vaccine is safe and highly immunogenic. Its use can be useful in subjects at risk of infections transmitted by the fecal-oral route, such as travellers from developed to developing countries.

AB - A clinical trial was conducted on 44 healthy young volunteers in order to assess the immunogenicity and safety of an inactivated hepatitis A vaccine. The preparation was injected intramuscularly in the deltoid region at month 0, 1, 6 and the serological follow-up was carried out at month 1, 2, 6, 7, 12. Each sample was tested for total anti-HAV with a new experimental kit manufactured by Boehringer Mannheim (B.M.) (Germany). Results were expressed as mIU/ml. Side effects after vaccine administration were relatively unfrequent and resulted to be mild, the most frequent being local pain at the site of injection. Seroconversion rates were 97.6% at month 1 and 100% at month 2. At all the following times (month 6, 7, 12) the presence of antibodies was maintained in all subjects. Anti-HAV Geometric Mean Titres resulted to be 379, 402, 486, 3917 and 1489 mIU/ml at month 1, 2, 6, 7 and 12 respectively. Two different kinetics of antibody response were noted at month 1 and 2. Most vaccinees increased their antibody titre after the second dose; some of them, however, showed a decrease of antibody titre after the second dose when compared to that achieved after the first one. Preliminary tests seem to explain such a behaviour with a decrease of IgM antibodies not yet compensated by an increase of IgG. The results of our study show how the inactivated hepatitis A vaccine is safe and highly immunogenic. Its use can be useful in subjects at risk of infections transmitted by the fecal-oral route, such as travellers from developed to developing countries.

UR - http://www.scopus.com/inward/record.url?scp=0027759741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027759741&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0027759741

VL - 33

SP - 111

EP - 115

BT - Journal of Preventive Medicine and Hygiene

ER -